Skip to content

Cogent Biosciences, Inc.

COGT· NasdaqCore metricsCIK 1622229

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -0.85%
Market cap
$5.07B
173.99M shares
Filings
616
$7.87M
FY 2020−65.0% FY20 yoy
-$111.43M
Q3 2026N/M FY25 yoy
-$117.18M
Q3 2026N/M FY25 yoy
-$245.87M
Q3 2026derivedN/M FY25 yoy
-$0.59
Q3 2026N/M FY25 yoy
$217.46M
Q3 2026+217.8% FY25 yoy
$5.07B
—
—
9.8×
-5.25%
—

FY2025 figures · derived

Price

$29.1312.84%$4.29past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$7.87MFY 2020
$22.50M0FY 2017FY 2018FY 2019FY 2020
PeriodEndedValueKindSource trail
FY 20202020-12-31$7,871,000reported
FY 20192019-12-31$22,499,000reported
FY 20182018-12-31$9,734,000reported
FY 20172017-12-31$8,360,000reported

Segments

Segments
Operating income by Segments, FY2022 to FY2025FY2022Late-stage Development · FY2022 · $61.27MR&D Personnel Related · FY2022 · $26.42MStock-Based Compensation Expense · FY2022 · $18.37MOther Operational Infrastructure and Advisory Support · FY2022 · $21.61MEarly-stage, Preclinical and Discovery Programs · FY2022 · $12.96MResearch and Development Software, Facilities and Other Strategic Support · FY2022 · $6.38MDepreciation Expense · FY2022 · $842.00KFY2023Late-stage Development · FY2023 · $85.48MR&D Personnel Related · FY2023 · $38.21MStock-Based Compensation Expense · FY2023 · $30.62MOther Operational Infrastructure and Advisory Support · FY2023 · $23.01MEarly-stage, Preclinical and Discovery Programs · FY2023 · $19.17MResearch and Development Software, Facilities and Other Strategic Support · FY2023 · $9.37MDepreciation Expense · FY2023 · $2.26MFY2024Late-stage Development · FY2024 · $120.86MR&D Personnel Related · FY2024 · $47.05MStock-Based Compensation Expense · FY2024 · $39.74MOther Operational Infrastructure and Advisory Support · FY2024 · $26.89MEarly-stage, Preclinical and Discovery Programs · FY2024 · $28.14MResearch and Development Software, Facilities and Other Strategic Support · FY2024 · $10.81MDepreciation Expense · FY2024 · $2.45MFY2025Late-stage Development · FY2025 · $120.06MR&D Personnel Related · FY2025 · $64.04MStock-Based Compensation Expense · FY2025 · $46.08MOther Operational Infrastructure and Advisory Support · FY2025 · $40.43MEarly-stage, Preclinical and Discovery Programs · FY2025 · $40.11MResearch and Development Software, Facilities and Other Strategic Support · FY2025 · $20.09MDepreciation Expense · FY2025 · $2.56M
LineFY2025ShareChange
Late-stage Development$120.06M—−0.7%
R&D Personnel Related$64.04M—+36.1%
Stock-Based Compensation Expense$46.08M—+16.0%
Other Operational Infrastructure and Advisory Support$40.43M—+50.4%
Early-stage, Preclinical and Discovery Programs$40.11M—+42.5%
Research and Development Software, Facilities and Other Strategic Support$20.09M—+85.8%
Depreciation Expense$2.56M—+4.7%
Total-$333.36M

From the 10-K filed Feb 17, 2026COGT

Pharmaceutical preparations

Cogent Biosciences, Inc. is the 53rd largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Cogent Biosciences, Inc. · CIK 1622229 · Engraved from SEC EDGAR